Edwards Lifesciences Corporation
EWNYSEHealthcare● Active
$85.33
$-0.63(-0.73%)
Market Cap$49.1B
P/E Ratio—
52W High$89.445
52W Low$72.3
Edwards Lifesciences Corporation (EW) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EW · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 23, 2026EPS Actual
$0.78
Est. $0.73 · +7.0%
Revenue
$1.65B
Est. $1.60B · +3.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 23, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
EW reports quarterly as a NYSE-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | $0.73 | — | — | — | $1.70B | — |
| ▲ Q2 FY2026 | Apr 23, 2026 | $0.73 | $0.78 | +7.0% | $1.65B | $1.60B | +3.2% |
| ▼ Q1 FY2026 | Feb 10, 2026 | $0.62 | $0.58 | -6.2% | $1.57B | $1.55B | +1.5% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.60 | $0.67 | +12.4% | $1.55B | $1.50B | +3.7% |
| ▲ Q3 FY2025 | Jul 24, 2025 | $0.62 | $0.67 | +7.4% | $1.53B | $1.49B | +3.0% |
| ▲ Q2 FY2025 | Apr 23, 2025 | $0.60 | $0.64 | +7.4% | $1.41B | $1.40B | +0.9% |
| ▲ Q1 FY2025 | Feb 11, 2025 | $0.55 | $0.59 | +7.1% | $1.39B | $1.36B | +2.0% |
| — Q4 FY2024 | Oct 24, 2024 | $0.67 | $0.67 | +0.8% | $1.35B | $1.54B | -12.3% |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
$0.73
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 23, 2026Beat
EPS Actual
$0.78
EPS Est.
$0.73
EPS Surpr.
+7.0%
Revenue
$1.65B
Q1 FY2026
Feb 10, 2026Miss
EPS Actual
$0.58
EPS Est.
$0.62
EPS Surpr.
-6.2%
Revenue
$1.57B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.67
EPS Est.
$0.60
EPS Surpr.
+12.4%
Revenue
$1.55B
Q3 FY2025
Jul 24, 2025Beat
EPS Actual
$0.67
EPS Est.
$0.62
EPS Surpr.
+7.4%
Revenue
$1.53B
Q2 FY2025
Apr 23, 2025Beat
EPS Actual
$0.64
EPS Est.
$0.60
EPS Surpr.
+7.4%
Revenue
$1.41B
Q1 FY2025
Feb 11, 2025Beat
EPS Actual
$0.59
EPS Est.
$0.55
EPS Surpr.
+7.1%
Revenue
$1.39B
Q4 FY2024
Oct 24, 2024
EPS Actual
$0.67
EPS Est.
$0.67
EPS Surpr.
+0.8%
Revenue
$1.35B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.93 | $0.94 | $0.95 | 15 |
| Q3 FY2028 | $0.97 | $0.98 | $0.99 | 8 |
| Q2 FY2028 | $0.96 | $0.98 | $0.99 | 8 |
| Q1 FY2028 | $0.94 | $0.95 | $0.96 | 11 |
| Q4 FY2027 | $0.83 | $0.84 | $0.85 | 14 |
| Q3 FY2027 | $0.84 | $0.85 | $0.86 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.1B | $2.1B | $2.1B | 14 |
| Q3 FY2028 | $2.0B | $2.1B | $2.1B | 7 |
| Q2 FY2028 | $2.0B | $2.0B | $2.1B | 7 |
| Q1 FY2028 | $2.0B | $2.0B | $2.0B | 10 |
| Q4 FY2027 | $1.9B | $1.9B | $1.9B | 15 |
| Q3 FY2027 | $1.8B | $1.9B | $1.9B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 23, 2026 | +7.0% | $81.53 | $79.72 | -2.22% |
| ▼ Q1 FY2026 | Feb 10, 2026 | -6.2% | $76.80 | $77.05 | +0.33% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +12.4% | $82.69 | $83.48 | +0.96% |
| ▲ Q3 FY2025 | Jul 24, 2025 | +7.4% | $76.91 | $75.80 | -1.44% |
| ▲ Q2 FY2025 | Apr 23, 2025 | +7.4% | $70.60 | $70.46 | -0.20% |
| ▲ Q1 FY2025 | Feb 11, 2025 | +7.1% | $71.10 | $70.91 | -0.27% |
| ▲ Q4 FY2024 | Oct 24, 2024 | +0.8% | $70.61 | $70.35 | -0.37% |
| ▲ Q3 FY2024 | Jul 24, 2024 | +1.4% | $87.05 | $86.95 | -0.11% |
Q2 FY2026-2.22%
Report Date
Apr 23, 2026
EPS Beat/Miss
+7.0%
Price Before
$81.53
Price After
$79.72
Q1 FY2026+0.33%
Report Date
Feb 10, 2026
EPS Beat/Miss
-6.2%
Price Before
$76.80
Price After
$77.05
Q4 FY2025+0.96%
Report Date
Oct 30, 2025
EPS Beat/Miss
+12.4%
Price Before
$82.69
Price After
$83.48
Q3 FY2025-1.44%
Report Date
Jul 24, 2025
EPS Beat/Miss
+7.4%
Price Before
$76.91
Price After
$75.80
Q2 FY2025-0.20%
Report Date
Apr 23, 2025
EPS Beat/Miss
+7.4%
Price Before
$70.60
Price After
$70.46
Q1 FY2025-0.27%
Report Date
Feb 11, 2025
EPS Beat/Miss
+7.1%
Price Before
$71.10
Price After
$70.91
Q4 FY2024-0.37%
Report Date
Oct 24, 2024
EPS Beat/Miss
+0.8%
Price Before
$70.61
Price After
$70.35
Q3 FY2024-0.11%
Report Date
Jul 24, 2024
EPS Beat/Miss
+1.4%
Price Before
$87.05
Price After
$86.95
Avg Beat Reaction-0.52%
Avg Miss Reaction+0.33%
Beat Rate7 / 8 quarters
Largest Move-2.22% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EW ends December
Edwards Lifesciences Corporation (EW) most recently reported earnings on April 23, 2026 for Q2 FY2026, posting EPS of $0.78 — beating the analyst consensus of $0.73 by +7.0%. The next EW earnings date is expected around September 1, 2026.
Each quarter, investors track EW earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EW revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EW's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EW earnings · 5 questionsEdwards Lifesciences Corporation's next earnings report is expected around September 1, 2026. EW typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EW historically reports after market close (AMC).
EW earnings datewhen is EW earningsEW next earnings datewhen does EW report earningsEW earnings calendar
▸ Source: FMP · Edwards Lifesciences Corporation SEC filings · US GAAP · Edwards Lifesciences Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026